Abstract
Poly(ADP-ribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and to also selectively kill homologous recombination repair-defective cancers, such as those arising in BRCA1 and BRCA2 mutation carriers. Recent proof-of-concept clinical studies have demonstrated the safety and substantial antitumor activity of the PARP inhibitor, olaparib in BRCA1/2 mutation carriers, highlighting the wide therapeutic window that can be achieved with this synthetic lethal strategy. Likewise, the PARP inhibitor, BSI-201, in combination with carboplatin and gemcitabine have produced promising results in “triple-negative” breast cancers. There are also currently numerous other PARP inhibitors in clinical development. The potential broader therapeutic application of these approaches to a wide range of sporadic tumors harboring specific defects in the homologous recombination repair pathway has generated a great deal of excitement within the oncology community. This review discusses the rationale for targeting PARP and details the strategies and challenges involved in the clinical development of such inhibitors and their future potential applications in cancer medicine.
Keywords: BRCA1, BRCA2, homologous recombination, PARP inhibitors, synthetic lethality, cancer, Base Excision Repair, combination therapy, clinical trials, Poly(ADP-Ribose) Polymerase Inhibitors
Current Drug Targets
Title: The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment
Volume: 12 Issue: 14
Author(s): Shahneen K. Sandhu, Timothy A. Yap and Johann S. de Bono
Affiliation:
Keywords: BRCA1, BRCA2, homologous recombination, PARP inhibitors, synthetic lethality, cancer, Base Excision Repair, combination therapy, clinical trials, Poly(ADP-Ribose) Polymerase Inhibitors
Abstract: Poly(ADP-ribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and to also selectively kill homologous recombination repair-defective cancers, such as those arising in BRCA1 and BRCA2 mutation carriers. Recent proof-of-concept clinical studies have demonstrated the safety and substantial antitumor activity of the PARP inhibitor, olaparib in BRCA1/2 mutation carriers, highlighting the wide therapeutic window that can be achieved with this synthetic lethal strategy. Likewise, the PARP inhibitor, BSI-201, in combination with carboplatin and gemcitabine have produced promising results in “triple-negative” breast cancers. There are also currently numerous other PARP inhibitors in clinical development. The potential broader therapeutic application of these approaches to a wide range of sporadic tumors harboring specific defects in the homologous recombination repair pathway has generated a great deal of excitement within the oncology community. This review discusses the rationale for targeting PARP and details the strategies and challenges involved in the clinical development of such inhibitors and their future potential applications in cancer medicine.
Export Options
About this article
Cite this article as:
K. Sandhu Shahneen, A. Yap Timothy and S. de Bono Johann, The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment, Current Drug Targets 2011; 12 (14) . https://dx.doi.org/10.2174/138945011798829438
DOI https://dx.doi.org/10.2174/138945011798829438 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry The Role of EGCG in Breast Cancer Prevention and Therapy.
Mini-Reviews in Medicinal Chemistry Aqueous Extract of Arbutus unedo Inhibits STAT1 Activation in Human Breast Cancer Cell Line MDA-MB-231 and Human Fibroblasts Through SHP2 Activation
Medicinal Chemistry ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy
Current Gene Therapy Best Practices and Emerging Trends for Market Access to Personalised Medicine in the US and EU: Learnings for Global Developed and Emerging Markets
Current Pharmacogenomics and Personalized Medicine Antibody-directed Double Suicide Gene Therapy Targeting of MUC1- Positive Leukemia Cells In Vitro and In Vivo
Current Gene Therapy Protective Role of Natural Products in Glioblastoma Multiforme: A Focus on Nitric Oxide Pathway
Current Medicinal Chemistry DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Vitamin D as a Potential Therapeutic Option in Cancer Treatment: Is There a Role for Chemoprevention?
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Integrated Application of Enhanced Replacement Method and Ensemble Learning for the Prediction of BCRP/ABCG2 Substrates
Current Bioinformatics Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Heteroaromatization with 4-Phenyldiazenyl-1-naphthol. Part IV: Synthesis of Some New Heterocyclic Compounds with Potential Biological Activity
Current Organic Synthesis Nanoparticles in Cancer
Current Radiopharmaceuticals Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis